---
title: Neuromuscular Blockers
type: content
phase: 1
status: complete
priority: high
tags: [neuromuscular-blockers, neuromuscular-junction, depolarizing, non-depolarizing, succinylcholine, rocuronium, anesthesia]
created: 2025-11-08
last_modified: 2025-11-08
---

# Neuromuscular Blockers

## Introduction

Neuromuscular blocking agents (NMBAs), also called muscle relaxants, are drugs that block neuromuscular transmission at the neuromuscular junction (NMJ), causing skeletal muscle paralysis. They are essential in anesthesiology for facilitating endotracheal intubation, providing surgical relaxation, and enabling mechanical ventilation. Understanding these drugs is critical for safe anesthetic practice.

## Neuromuscular Junction Physiology

### Structure

**Presynaptic Terminal** (motor neuron):
- Voltage-gated Ca2+ channels
- ACh-containing vesicles
- Choline reuptake mechanism

**Synaptic Cleft**: 20-50 nm space
- Contains acetylcholinesterase (AChE)

**Postsynaptic Membrane** (muscle end-plate):
- High density of nicotinic receptors (Nm)
- Adult: (α1)2β1δε
- Fetal/denervated: (α1)2β1δγ (different pharmacology)

### Normal Neurotransmission

1. Action potential arrives → Ca2+ influx
2. ACh vesicle fusion and release
3. ACh binds nicotinic receptors (need both α subunits occupied)
4. Na+ influx, K+ efflux → end-plate potential (EPP)
5. EPP reaches threshold → muscle action potential → contraction
6. ACh rapidly hydrolyzed by AChE
7. Choline reuptake and ACh resynthesis

**Margin of Safety**: 
- ~50% receptor occupancy needed for normal transmission
- NMBAs must block >70-80% receptors for clinical paralysis

---

## Classification of Neuromuscular Blockers

### 1. Depolarizing Agents
- Succinylcholine (only one in clinical use)

### 2. Non-Depolarizing Agents

**By Chemical Structure**:
- **Aminosteroids**: Rocuronium, vecuronium, pancuronium, pipecuronium
- **Benzylisoquinolines**: Atracurium, cisatracurium, mivacurium, doxacurium

**By Duration**:
- **Ultra-short**: Succinylcholine (5-10 min)
- **Short**: Mivacurium (15-20 min)
- **Intermediate**: Rocuronium, vecuronium, atracurium, cisatracurium (30-40 min)
- **Long**: Pancuronium, doxacurium, pipecuronium (60-90 min)

---

## Depolarizing Neuromuscular Blockers

### Succinylcholine (Suxamethonium)

**Structure**: Two ACh molecules joined end-to-end

**Mechanism of Action**:

**Phase I Block** (depolarizing):
1. Binds and activates nicotinic receptors
2. Sustained depolarization (not rapidly hydrolyzed by AChE)
3. Initial fasciculations (muscle twitches)
4. End-plate remains depolarized → inactivation of voltage-gated Na+ channels
5. Muscle cannot repolarize and contract → flaccid paralysis

**Phase II Block** (desensitization):
- With prolonged exposure (rare)
- Resembles non-depolarizing block
- Can occur with large/repeated doses or pseudocholinesterase deficiency

**Pharmacokinetics**:

**Metabolism**:
- Rapidly hydrolyzed by **plasma cholinesterase** (butyrylcholinesterase, pseudocholinesterase)
- NOT metabolized by acetylcholinesterase
- Metabolites: Succinylmonocholine (weak activity) → succinic acid + choline

**Duration**: 
- 5-10 minutes (IV bolus)
- Ultra-short compared to non-depolarizing agents

**Onset**:
- 30-60 seconds (fastest of all NMBAs)
- Ideal for rapid sequence intubation (RSI)

**Elimination**:
- Plasma hydrolysis (not renal/hepatic)
- Only ~10% reaches NMJ

**Clinical Uses**:

1. **Rapid Sequence Intubation (RSI)**
   - Fastest onset
   - Short duration
   - Emergent intubations
   - Full stomach (aspiration risk)

2. **Brief procedures**
   - Electroconvulsive therapy (ECT)
   - Laryngoscopy
   - Reduction of dislocations

**Adverse Effects**:

**1. Fasciculations**:
- Muscle twitching before paralysis
- Mechanism: Initial receptor activation
- Consequence: Myalgia (muscle pain) postoperatively
- Prophylaxis: "Defasciculating dose" of non-depolarizing agent (controversial)

**2. Hyperkalemia** (most serious):
- Normal: ↑K+ by 0.5 mEq/L
- **Massive K+ release** in:
  - Burns (>24h old)
  - Denervation injuries (spinal cord injury, stroke)
  - Prolonged immobilization
  - Muscular dystrophy, myopathies
  - Massive trauma
  - Severe infection
- Mechanism: Upregulation of extrajunctional ACh receptors (fetal form)
- Can cause **cardiac arrest**
- **Avoid** in these patients

**Contraindications** (hyperkalemia risk):
- Burns >24-48 hours old
- Denervation injuries (>24-48h)
- Chronic immobilization
- Muscular dystrophy (Duchenne)
- Severe trauma, crush injuries
- Known hyperkalemia

**3. Malignant Hyperthermia (MH)**:
- Rare, life-threatening
- Genetic disorder (RYR1 mutations - ryanodine receptor)
- Triggered by succinylcholine + volatile anesthetics
- **Presentation**: Hyperthermia, muscle rigidity, hypermetabolism, rhabdomyolysis, acidosis, hyperkalemia
- **Treatment**: Dantrolene (blocks Ca2+ release from sarcoplasmic reticulum), supportive care, cooling
- **Mortality**: ~5% (was 80% before dantrolene)

**Early sign**: Masseter spasm (jaw rigidity) after succinylcholine

**4. Increased Intraocular Pressure (IOP)**:
- Extraocular muscle contraction → ↑IOP (5-10 mmHg)
- Relative contraindication: Open globe injury (theoretical risk of extrusion)
- Controversial clinical significance

**5. Increased Intragastric Pressure**:
- Fasciculations → ↑abdominal muscle tone → ↑gastric pressure
- Theoretical aspiration risk (offset by faster intubation)

**6. Increased Intracranial Pressure (ICP)**:
- Transient ↑ICP
- Use with caution in head injury (controversial)

**7. Bradycardia**:
- Especially second dose or children
- Muscarinic (M2) activation
- Prevented with atropine

**8. Prolonged Paralysis** (Pseudocholinesterase Deficiency):

**Genetic Variants**:
- Atypical pseudocholinesterase (butyrylcholinesterase)
- Autosomal recessive
- Homozygous: 1 in 3,000
- Heterozygous: 1 in 25

**Clinical Effect**:
- Normal: 5-10 min paralysis
- Heterozygous: 20-30 min
- Homozygous: 4-8 hours

**Diagnosis**:
- Dibucaine number (measures enzyme quality)
- Normal: >80 (dibucaine inhibits normal enzyme)
- Atypical: <30 (dibucaine doesn't inhibit)

**Management**:
- Mechanical ventilation until recovery
- Consider fresh frozen plasma (contains normal enzyme)
- Avoid succinylcholine in future
- Family screening

**Acquired Pseudocholinesterase Deficiency**:
- Liver disease
- Malnutrition
- Pregnancy
- Organophosphate exposure
- Drugs: Echothiophate, metoclopramide, esmolol

**9. Myoglobinuria**:
- Muscle damage from fasciculations
- Can lead to renal failure (rare)

**10. Trismus** (jaw rigidity):
- May herald malignant hyperthermia

**Drug Interactions**:
- **Potentiation**: Aminoglycosides, local anesthetics, magnesium
- **Prolongation**: Organophosphates, echothiophate (cholinesterase inhibitors)

**Reversal**: 
- **None specific**
- Allow spontaneous recovery (if normal pseudocholinesterase)
- **NOT reversed by anticholinesterases** (neostigmine/pyridostigmine would worsen Phase I block)

**Contraindications**:
- Personal/family history of malignant hyperthermia
- Muscular dystrophy
- Risk of hyperkalemia (see above)
- Known pseudocholinesterase deficiency
- Relative: Penetrating eye injury, severe burns

---

## Non-Depolarizing Neuromuscular Blockers

### Mechanism of Action

**Competitive Antagonism** at nicotinic receptors:
- Bind to α subunits without activating
- Prevent ACh from binding
- No depolarization
- **No fasciculations**
- Reversible with anticholinesterases (neostigmine, edrophonium)

**Characteristics of Non-Depolarizing Block**:
- Fade with tetanic stimulation (train-of-four)
- Post-tetanic facilitation
- Reversed by anticholinesterases
- Potentiated by aminoglycosides, volatile anesthetics

### Aminosteroid NMBAs

**Rocuronium**:

**Characteristics**:
- Intermediate duration (30-40 min)
- **Rapid onset** (60-90 seconds at high dose)
- Alternative to succinylcholine for RSI
- Minimal cardiovascular effects

**Pharmacokinetics**:
- Hepatic uptake and biliary excretion (70%)
- Renal excretion (30%)
- Prolonged in liver disease

**Dosing**:
- Intubation: 0.6-1.2 mg/kg IV
- Higher dose → faster onset (approaches succinylcholine)

**Reversal**:
- Neostigmine (traditional)
- **Sugammadex** (specific reversal, very rapid - see below)

**Advantages**:
- Rapid onset (high dose)
- Hemodynamically stable
- Specific reversal available (sugammadex)

**Vecuronium**:

**Characteristics**:
- Intermediate duration (30-40 min)
- Moderate onset (2-3 min)
- Minimal cardiovascular effects (no histamine, no vagolysis)

**Pharmacokinetics**:
- Hepatic metabolism and biliary excretion
- Some renal excretion
- Prolonged in liver disease

**Dosing**: 0.08-0.1 mg/kg IV

**Advantages**:
- Hemodynamically stable (ideal for cardiac surgery)
- No cumulative effect (with appropriate dosing intervals)

**Pancuronium**:

**Characteristics**:
- Long duration (60-90 min)
- Slow onset (3-5 min)

**Cardiovascular Effects**:
- **Vagolysis** (blocks M2 receptors) → tachycardia
- Sympathomimetic (↑NE release)
- ↑HR, ↑BP
- Beneficial in some situations (↓anesthetic-induced bradycardia)

**Pharmacokinetics**:
- Renal excretion (80%)
- Some hepatic metabolism
- Prolonged in renal failure

**Dosing**: 0.08-0.1 mg/kg IV

**Uses**:
- Long procedures
- Less commonly used now (intermediate agents preferred)

**Pipecuronium**: 
- Long-acting, similar to pancuronium but minimal cardiovascular effects
- Rarely used

### Benzylisoquinoline NMBAs

**Atracurium**:

**Characteristics**:
- Intermediate duration (30-40 min)
- Moderate onset (2-3 min)

**Unique Pharmacokinetics**:
- **Hofmann elimination** (spontaneous degradation at body pH and temperature)
  - Non-enzymatic, pH/temperature-dependent
  - Independent of liver and kidney function
- **Ester hydrolysis** (plasma esterases)
- Metabolite: **Laudanosine** (CNS stimulant - seizures in high doses, usually not clinically significant)

**Advantages**:
- Predictable duration even in organ failure
- Ideal for renal/hepatic failure

**Adverse Effects**:
- **Histamine release** → hypotension, bronchospasm, flushing
- Dose-dependent, minimized by slow injection
- Laudanosine accumulation (theoretical concern in prolonged infusions)

**Dosing**: 0.4-0.5 mg/kg IV

**Cisatracurium**:

**Relationship**: Stereoisomer of atracurium (1 of 10 isomers)

**Advantages over atracurium**:
- 3-4x more potent
- **Minimal histamine release** (major advantage)
- Same elimination (Hofmann)
- Lower laudanosine levels

**Characteristics**:
- Intermediate duration (30-40 min)
- Minimal cardiovascular effects
- Ideal for organ failure patients

**Pharmacokinetics**: Same as atracurium (Hofmann + ester hydrolysis)

**Dosing**: 0.15-0.2 mg/kg IV

**Uses**:
- Preferred benzylisoquinoline (less histamine than atracurium)
- Renal/hepatic failure
- Patients at risk for hemodynamic instability

**Mivacurium**:

**Characteristics**:
- **Short duration** (15-20 min)
- Moderate onset (2-3 min)

**Metabolism**:
- Plasma cholinesterase (like succinylcholine)
- Prolonged in pseudocholinesterase deficiency

**Adverse Effects**:
- Histamine release (dose-dependent)
- Hypotension, flushing

**Dosing**: 0.15-0.2 mg/kg IV

**Advantages**: 
- Shorter than intermediate agents
- Allows spontaneous recovery without reversal

**Disadvantages**:
- Histamine release
- Largely replaced by smaller doses of intermediate agents

**Doxacurium**:
- Long-acting benzylisoquinoline
- Rarely used

---

## Factors Affecting NMBA Action

### Potentiation (Enhanced Block)

**Volatile Anesthetics**:
- Dose-dependent potentiation
- Mechanism: ↓ACh release, ↓postjunctional sensitivity
- Reduce NMBA dose requirement by 15-30%
- Desflurane > sevoflurane > isoflurane > propofol (none)

**Aminoglycoside Antibiotics**:
- Inhibit presynaptic ACh release
- Stabilize postsynaptic membrane
- Can prolong paralysis
- May require reversal

**Magnesium**:
- Blocks Ca2+ channels → ↓ACh release
- Potentiates NMBAs
- Seen in preeclampsia treatment

**Local Anesthetics**:
- High systemic concentrations
- Inhibit ACh release

**Other Drugs**:
- Calcium channel blockers
- Furosemide
- Lithium
- Dantrolene

**Hypothermia**:
- Slows metabolism and elimination
- Prolongs block

**Acidosis**:
- Respiratory or metabolic
- Potentiates block

**Electrolyte Abnormalities**:
- Hypokalemia, hypermagnesemia, hypocalcemia
- Enhance blockade

### Resistance (Reduced Block)

**Upregulation of Receptors**:
- Denervation (>24-48h)
- Burns (>24-48h)
- Immobilization
- Mechanism: Extrajunctional receptor proliferation → require higher NMBA doses
- Same conditions cause succinylcholine hyperkalemia

**Anticonvulsants** (chronic use):
- Phenytoin, carbamazepine
- Enzyme induction → faster metabolism (aminosteroids)
- Receptor upregulation
- Require 30-50% higher doses

**Hyperkalemia**:
- Shifts membrane potential away from threshold

---

## Monitoring Neuromuscular Blockade

### Train-of-Four (TOF) Stimulation

**Method**:
- 4 supramaximal stimuli at 2 Hz (0.5 sec intervals)
- Usually ulnar nerve → adductor pollicis (thumb) contraction

**Interpretation**:

**TOF Count** (number of visible twitches):
- 4 twitches: <75% receptors blocked (inadequate for surgery)
- 3 twitches: ~75% blocked
- 2 twitches: ~80% blocked
- 1 twitch: ~90% blocked
- 0 twitches: >95% blocked (adequate for surgery)

**TOF Ratio** (T4/T1 - fourth twitch/first twitch amplitude):
- Normal: 1.0 (no fade)
- >0.9: Safe for extubation (adequate reversal)
- 0.7-0.9: Partial recovery (risk of aspiration, weakness)
- <0.7: Significant residual blockade

**Fade**: Progressive decrease in twitch amplitude (characteristic of non-depolarizing block)
- No fade with depolarizing block (Phase I)

**Post-Tetanic Potentiation**:
- Tetanic stimulation (50 Hz for 5 sec) → followed by TOF
- Temporary enhancement of twitch after tetanus
- Helps detect deep block
- Seen with non-depolarizing, not depolarizing

**Double-Burst Stimulation (DBS)**:
- More sensitive for detecting fade
- Two short bursts separated by 750 ms

**Clinical Assessment** (less reliable):
- 5-second head lift
- Grip strength
- Vital capacity >15 mL/kg
- Negative inspiratory force < -20 cm H2O

---

## Reversal of Neuromuscular Blockade

### Anticholinesterases

**Neostigmine**:

**Mechanism**:
- Inhibits acetylcholinesterase
- ↑ACh at NMJ → competes with non-depolarizing NMBA

**Pharmacokinetics**:
- IV only for reversal
- Onset: 5-10 min
- Peak: 10-15 min
- Duration: 30-60 min
- Quaternary amine (doesn't cross BBB)

**Dosing**: 0.04-0.07 mg/kg IV (max 5 mg)

**Limitations**:
- **Cannot reverse deep block** (TOF count 0)
  - Need at least 1-2 twitches for effective reversal
- Slower than sugammadex
- Muscarinic side effects (requires atropine/glycopyrrolate)

**Muscarinic Side Effects**:
- Bradycardia
- Bronchospasm
- Increased secretions
- GI cramping

**Co-administration**:
- **Atropine** or **glycopyrrolate** (anticholinergic)
- Prevents muscarinic side effects
- Usual: Neostigmine 0.05 mg/kg + glycopyrrolate 0.01 mg/kg

**Edrophonium**:
- Shorter-acting than neostigmine
- Less commonly used for reversal
- Dose: 0.5-1 mg/kg IV

**Pyridostigmine**:
- Longer onset and duration than neostigmine
- Rarely used for acute reversal

### Sugammadex

**Mechanism**:
- Modified γ-cyclodextrin (encapsulating agent)
- **Selective binding** (encapsulation) of rocuronium and vecuronium
- Forms 1:1 complex
- Rapidly ↓free NMBA concentration
- NMBA dissociates from receptors down concentration gradient

**Characteristics**:
- **Rapid reversal** (1-3 minutes)
- **Reverses any depth of block** (including cannot intubate/cannot ventilate)
- No muscarinic effects (no atropine/glycopyrrolate needed)
- Specific for aminosteroid NMBAs (rocuronium, vecuronium)
  - Does NOT work for: Succinylcholine, cisatracurium, atracurium, mivacurium

**Pharmacokinetics**:
- IV administration
- Renal excretion (as sugammadex-rocuronium complex)
- Not metabolized

**Dosing**:
- **Moderate block** (TOF 2-4): 2 mg/kg
- **Deep block** (TOF 1-2): 4 mg/kg
- **Immediate reversal** (3 min post-rocuronium): 16 mg/kg
  - "Cannot intubate, cannot ventilate" scenario

**Advantages**:
- Rapid, complete reversal
- Reverses deep block (neostigmine cannot)
- No anticholinergic needed
- Predictable, dose-dependent
- Safer profile

**Adverse Effects**:
- Generally well-tolerated
- Rare: Bradycardia, bronchospasm (hypersensitivity)
- Metallic taste

**Drug Interactions**:
- **Hormonal contraceptives**: May reduce efficacy for 7 days after sugammadex
  - Recommend backup contraception
- **Toremifene**: Displaced by sugammadex

**Contraindications**:
- Severe renal impairment (CrCl <30) - relative
- Allergy to sugammadex

**Cost**: Expensive (limits use in some settings)

**Clinical Use**:
- Increasingly used (when cost not prohibitive)
- Essential for "cannot intubate, cannot ventilate"
- Allows rapid emergence from deep block

---

## Clinical Pearls

1. **Succinylcholine is fastest onset**: 30-60 sec (RSI drug of choice)
2. **Succinylcholine causes hyperkalemia**: Avoid in burns, denervation, immobilization >24-48h
3. **Malignant hyperthermia**: Triggered by succinylcholine + volatiles; treat with dantrolene
4. **Pseudocholinesterase deficiency**: Prolongs succinylcholine (hours); support until recovery
5. **Rocuronium + sugammadex**: Alternative to succinylcholine for RSI
6. **TOF ratio >0.9 for safe extubation**: Assess adequacy of reversal
7. **Neostigmine requires 1-2 twitches**: Cannot reverse deep block
8. **Sugammadex reverses any depth**: Including immediate post-rocuronium
9. **Cisatracurium in organ failure**: Hofmann elimination (independent of kidneys/liver)
10. **Aminoglycosides potentiate NMBAs**: May prolong paralysis
11. **Volatile anesthetics potentiate NMBAs**: Reduce dose requirement
12. **Atracurium releases histamine**: Hypotension, bronchospasm; cisatracurium better
13. **Pancuronium causes tachycardia**: Vagolysis (M2 blockade)
14. **No fasciculations with non-depolarizing**: Helps differentiate from succinylcholine
15. **Residual paralysis is common**: Up to 40% of patients; causes postoperative complications

---

## Key Takeaways

1. **NMBAs block nicotinic receptors at NMJ** → skeletal muscle paralysis
2. **Succinylcholine**: Depolarizing, fastest onset, short duration; causes fasciculations, hyperkalemia, MH
3. **Non-depolarizing NMBAs**: Competitive antagonists, no fasciculations, reversed by anticholinesterases
4. **Aminosteroids**: Rocuronium (rapid onset, sugammadex reversal), vecuronium (stable hemodynamics), pancuronium (tachycardia)
5. **Benzylisoquinolines**: Cisatracurium (Hofmann, organ failure), atracurium (histamine release)
6. **TOF monitoring**: Assesses depth of block; TOF >0.9 for safe extubation
7. **Neostigmine + glycopyrrolate**: Reverses non-depolarizing block (need 1-2 twitches)
8. **Sugammadex**: Specific for rocuronium/vecuronium; rapid, any depth, no anticholinergic needed
9. **Potentiation**: Volatiles, aminoglycosides, magnesium enhance block
10. **Resistance**: Burns, denervation, anticonvulsants reduce block

---

## References

1. Miller's Anesthesia, 9th Edition
2. Stoelting's Pharmacology & Physiology in Anesthetic Practice, 5th Edition
3. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
4. Clinical Anesthesia, Barash, 8th Edition
5. AANA Journal of Nurse Anesthesia
